A prospectively randomized, phase III, multicenter, controlled trial to evaluate the safety and efficacy of the Zevalin [ibritumomab tiuxetan Y-90] therapeutic regimen plus Rituxan [rituximab] compared with Rituxan alone in patients with relapsed or refractory follicular NHL [non-Hodgkin's lymphoma]

Trial Profile

A prospectively randomized, phase III, multicenter, controlled trial to evaluate the safety and efficacy of the Zevalin [ibritumomab tiuxetan Y-90] therapeutic regimen plus Rituxan [rituximab] compared with Rituxan alone in patients with relapsed or refractory follicular NHL [non-Hodgkin's lymphoma]

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Ibritumomab tiuxetan; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Oct 2006 Status change
    • 23 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top